PT  - JOURNAL ARTICLE
AU  - PATRICK GARNERO
AU  - NADINE CHARNI-BEN TABASSI
AU  - NATHALIE VOORZANGER-ROUSSELOT
TI  - Circulating Dickkopf-1 and Radiological Progression in Patients with Early Rheumatoid Arthritis Treated with Etanercept
AID  - 10.3899/jrheum.080356
DP  - 2008 Dec 01
TA  - The Journal of Rheumatology
PG  - 2313--2315
VI  - 35
IP  - 12
4099  - http://www.jrheum.org/content/35/12/2313.short
4100  - http://www.jrheum.org/content/35/12/2313.full
SO  - J Rheumatol2008 Dec 01; 35
AB  - Objective Dickkopf-1 (Dkk-1) regulates bone remodeling in animal models of inflammatory arthritis, but its role in patients with rheumatoid arthritis (RA) remains unclear. Methods Baseline circulating Dkk-1 was measured in 113 patients with RA (< 3 yrs) who received etanercept (10 or 25 mg twice/week, n = 63) or methotrexate alone (n = 40) for 1 year. Progression was assessed by changes in radiological Sharp score. Results Increased Dkk-1 was associated with a higher risk of progression of bone erosion, independently of age, sex, baseline radiological damage, C-reactive protein, and disease activity in patients treated with etanercept. Conclusion Dkk-1 may be an important mediator of bone erosion in patients with RA.